# Clinical profile of FTL3-ITD mutation in West Algerian population with acute myeloid leukemia

## TL;DR

This study reports the first prevalence of FLT3-ITD mutation in acute myeloid leukemia patients from West Algeria and its clinical associations.

## Contribution

First-time prevalence data of FLT3-ITD mutation in West Algerian AML patients and its clinical correlations.

## Key findings

- FLT3-ITD mutation was detected in 13% of AML patients.
- Mutation was associated with higher leukocyte and blast cell counts.
- M3 and M5 subtypes were most common in FLT3-mutated patients.

## Abstract

Acute myeloid leukemia (AML) is a cancer of the myeloid line of blood cells, characterized by the abnormal and rapid growth of cells. The mutation of the Fms-like tyrosine kinase 3 ligand gene (FLT3-ITD) represents an important factor in the prognosis of AML. The objective of this study was to determine for the first time the prevalence of FLT3-ITD mutation in west Algerian AML patients. A total of 160 AML patients were genotyped for FLT3-ITD mutation by using polymerase chain reaction. FLT3-ITD mutation was detected in 13% of patients. Mutation rates show no significant difference in the distribution of sex and age. A positive association was found between this mutation and a higher leukocyte and blast cells counts. We also found that the M3 and M5 subtype were the commonest in the FLT3 mutated group. This preliminary study provides first-time prevalence estimates for FLT3-ITD mutation in acute myeloid leukemia patients from the West region of Algeria.